172 related articles for article (PubMed ID: 23509924)
1. Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer: a Phase II pilot study.
Jensen EH; Armstrong L; Lee C; Tuttle TM; Vickers SM; Sielaff T; Greeno EW
HPB (Oxford); 2014 Feb; 16(2):131-9. PubMed ID: 23509924
[TBL] [Abstract][Full Text] [Related]
2. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
3. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
[TBL] [Abstract][Full Text] [Related]
4. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
Wanebo HJ; Glicksman AS; Vezeridis MP; Clark J; Tibbetts L; Koness RJ; Levy A
Arch Surg; 2000 Jan; 135(1):81-7; discussion 88. PubMed ID: 10636353
[TBL] [Abstract][Full Text] [Related]
5. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
[TBL] [Abstract][Full Text] [Related]
8. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
[TBL] [Abstract][Full Text] [Related]
9. Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol.
Rocha FG; Hashimoto Y; Traverso LW; Dorer R; Kozarek R; Helton WS; Picozzi VJ
Ann Surg; 2016 Feb; 263(2):376-84. PubMed ID: 25775069
[TBL] [Abstract][Full Text] [Related]
10. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Histological Basis of Adenosquamous Carcinoma of the Pancreas: A 30-year Experience.
Moslim MA; Lefton MD; Ross EA; Mackrides N; Reddy SS
J Surg Res; 2021 Mar; 259():350-356. PubMed ID: 33190924
[TBL] [Abstract][Full Text] [Related]
12. The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.
Lee JH; Kang CM; Bang SM; Choi JY; Seong JS; Hwang HK; Choi SH; Lee WJ
Medicine (Baltimore); 2015 Aug; 94(31):e1233. PubMed ID: 26252282
[TBL] [Abstract][Full Text] [Related]
13. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
14. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
15. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience.
Turrini O; Viret F; Moureau-Zabotto L; Guiramand J; Moutardier V; Lelong B; de Chaisemartin C; Giovannini M; Delpero JR
Oncology; 2009; 76(6):413-9. PubMed ID: 19407474
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
Golcher H; Brunner TB; Witzigmann H; Marti L; Bechstein WO; Bruns C; Jungnickel H; Schreiber S; Grabenbauer GG; Meyer T; Merkel S; Fietkau R; Hohenberger W
Strahlenther Onkol; 2015 Jan; 191(1):7-16. PubMed ID: 25252602
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant-intensified treatment for rectal cancer: time to change?
Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
[TBL] [Abstract][Full Text] [Related]
20. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]